Effect of metformin and insulin combination on monocyte chemoattractant protein-1 and cathepsin-D in type 2 diabetes mellitus.
Adult
Biomarkers
/ blood
Blood Glucose
/ analysis
Case-Control Studies
Cathepsin D
/ blood
Chemokine CCL2
/ blood
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ blood
Diabetic Retinopathy
/ blood
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Hypoglycemic Agents
/ therapeutic use
Insulin
/ therapeutic use
Male
Metformin
/ therapeutic use
Middle Aged
Prognosis
Prospective Studies
Young Adult
Cathepsin-D
Diabetic retinopathy
MCP-1
Type 2 diabetes mellitus
Journal
Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250
Informations de publication
Date de publication:
Historique:
received:
19
02
2020
revised:
13
08
2020
accepted:
15
08
2020
pubmed:
11
9
2020
medline:
5
10
2021
entrez:
10
9
2020
Statut:
ppublish
Résumé
Monocyte chemoattractant protein-1 (MCP-1) and cathepsin-D are progressively raised in type 2 diabetes mellitus (T2DM) with both non proliferative and proliferative retinal disease. This study aimed to evaluate the effect of antidiabetic medications on MCP-1 and cathepsin-D. 60 patients of T2DM without retinopathy and 60 of diabetic retinopathy were enrolled to receive metformin (500 mg-1000 mg) combined with either glimepiride (1 mg-2 mg) or insulin. The effect of antidiabetic medications on serum MCP-1 and cathepsin-D was assessed. Mean MCP-1 (pg/ml) and cathepsin-D (ng/ml) levels were significantly lower in patients of T2DM with and without retinopathy treated with metformin + insulin (468.52 ± 272.84 vs 234.30 ± 180.58; p < 0.01 and 460.15 ± 128.52 vs 517.33 ± 213.49; p = 0.214) as compared to patients treated with metformin + glimepiride (1434.02 ± 105.27 vs 1256.27 ± 76.76; p < 0.01 and 1689.36 ± 752.57 vs 919.69 ± 675.05; p = < 0.01). No significant correlation of MCP-1 and cathepsin-D with HbA1c, fasting and post prandial blood glucose were found. Patients treated with metformin and insulin combination had lower serum MCP-1 and cathepsin-D levels which suggests that this combination may be more effective in reducing the progression of diabetic retinopathy. (CTRI/2018/05/013601).
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Monocyte chemoattractant protein-1 (MCP-1) and cathepsin-D are progressively raised in type 2 diabetes mellitus (T2DM) with both non proliferative and proliferative retinal disease. This study aimed to evaluate the effect of antidiabetic medications on MCP-1 and cathepsin-D.
METHODS
METHODS
60 patients of T2DM without retinopathy and 60 of diabetic retinopathy were enrolled to receive metformin (500 mg-1000 mg) combined with either glimepiride (1 mg-2 mg) or insulin. The effect of antidiabetic medications on serum MCP-1 and cathepsin-D was assessed.
RESULTS
RESULTS
Mean MCP-1 (pg/ml) and cathepsin-D (ng/ml) levels were significantly lower in patients of T2DM with and without retinopathy treated with metformin + insulin (468.52 ± 272.84 vs 234.30 ± 180.58; p < 0.01 and 460.15 ± 128.52 vs 517.33 ± 213.49; p = 0.214) as compared to patients treated with metformin + glimepiride (1434.02 ± 105.27 vs 1256.27 ± 76.76; p < 0.01 and 1689.36 ± 752.57 vs 919.69 ± 675.05; p = < 0.01). No significant correlation of MCP-1 and cathepsin-D with HbA1c, fasting and post prandial blood glucose were found.
CONCLUSION
CONCLUSIONS
Patients treated with metformin and insulin combination had lower serum MCP-1 and cathepsin-D levels which suggests that this combination may be more effective in reducing the progression of diabetic retinopathy. (CTRI/2018/05/013601).
Identifiants
pubmed: 32911202
pii: S1871-4021(20)30319-2
doi: 10.1016/j.dsx.2020.08.016
pii:
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
CCL2 protein, human
0
Chemokine CCL2
0
Hypoglycemic Agents
0
Insulin
0
Metformin
9100L32L2N
CTSD protein, human
EC 3.4.23.5
Cathepsin D
EC 3.4.23.5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1703-1710Informations de copyright
Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None.